JAKs and STATs in Immunity, Immunodeficiency, and Cancer | NEJM
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases - Journal of Allergy and Clinical Immunology
JAK/STAT signaling in hematological malignancies | Oncogene
JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors | PNAS
Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata | Actas Dermo-Sifiliográficas
A MicroRNA-1–Mediated Inhibition of the NF-κB Pathway by the JAK-STAT Pathway in the Invertebrate Litopenaeus vannamei | The Journal of Immunology
Cells | Free Full-Text | Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy | HTML
:max_bytes(150000):strip_icc()/jak-inhibitors-4706526-FINAL-3461d4fc6ce44f54801ef59489afa62c.png "JAK Inhibitors: Uses, Drug Options, and Side Effects")
JAK Inhibitors: Uses, Drug Options, and Side Effects
SOCS induction by and inhibition of the JAK/STAT pathway. (1)... | Download Scientific Diagram
Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology | Immunology
JCI - JAK inhibitors in autoinflammation
Translational and clinical advances in JAK‐STAT biology: The present and future of jakinibs - Gadina - 2018 - Journal of Leukocyte Biology - Wiley Online Library
Signalling through the JAK–STAT pathway in the developing brain: Trends in Neurosciences
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19: Trends in Pharmacological Sciences
The role of JAK/STAT signaling pathway and its inhibitors in diseases - ScienceDirect
□ Janus激酶抑製劑的研究與開發 Research and Development of Janus Kinase (JAK) Inhibitors - 龍欣科技股份有限公司 EDRAGON TECHNOLOGY CORPORATION
Rheumatoid arthritis | JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis? | rheumatology.medicinematters.com
Figure 1 | JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors | SpringerLink
Ruxolitinib (INCB018424) | ≥99%(HPLC) | Selleck | JAK inhibitor
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application | Biomarker Research | Full Text
IJMS | Free Full-Text | Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms | HTML
